Excited to announce that after 4 rejections and countless moments of despair and almost giving up, I received my first Notice of Award for my first R01!
Huge thanks to @WilsonTangMD for incredible mentorship, CIRC, and our HVTI leadership, supporting and fostering innovation.
#EHJCVI 🔍 How is cardiovascular imaging reshaping VHD trials? This new review explores the expanding role of CV imaging across RCTs in different VHD, highlighting its impact on design, endpoints, and translation into clinical practice🫀📊 Read more 👉 https://t.co/NkUOgjdcxC
#EHJCVI 🩺 A new review shows how sex differences influence every stage of valvular heart disease, from aetiology to imaging features and timing of intervention 📊 Multimodality imaging is key to preventing underdiagnosis, especially in women 👉 https://t.co/rx6Y150Qsc
@GillesDreyfus on his TriSCORE #EACVI2025
What is the sweet spot to intervene on the tricuspid valve? Intervene earlier when procedure risk low & anatomic suitability high #echofirst annulus dilates anterior/posterior leaflets(not septal) larger closure area w 🍀 🆚 zipper
We just published a model that does automated data extraction from Cardiac MRI reports. Let AI help make chart reviewing easier and the data collection process faster.
Thank you Drs. @DebbieKwonMD & Chen for your mentorship on this project!
https://t.co/QHNWJEbeNp
🔥 You don’t want to miss #SCMR2026 in Rio de Janeiro!
We’re kicking off the meeting with an unmissable opening plenary by
🗣️ Steven Levine: “The Living Heart: How Digital Twins Are Transforming Cardiovascular Medicine” 🫀
For more informations 👉 https://t.co/DU9u5IIGCy
✨ SCMR is present at #EACVI2025! 🫀
We’re excited to be on site representing SCMR community and sharing upcoming initiatives and events.
If you're attending, stop by the booth and say hello!
#SCMR#CMR#CardiacImaging
Treat the valve AND the myocardium when facing severe AS+amyloidosis. Both AVR and tafamidis independently ↓ mortality
Dual therapy=best outcomes w/ similar survival to lone AS+AVR. Dual pathology is common (~13%) warranting RCT. https://t.co/q1wqnZSlZV Bravo @ThomasTreibel! 👏🏻
Age-specific troponin thresholds: considerations for the fifth universal definition of myocardial infarction in EHJ.
https://t.co/GrxYPXRZV4
@ESCardio@ESC_Journals#age#5UDMI@johnwmcevoy
One of the defining aspects of our fellowship are our accomplished alumni. As a part of our fellowship research day, Dr. Chhatriwalla honored us with a noon conference on advancements in ViV TAVR and bioprosthetic valve fracture! @akcmahi@venumenon10
@CleClinicCIRC turns 3 years old today and we celebrate all the wonderful research and hard work. I feel honored to work with this talented group of scientists, engineers, and clinicians developing novel CV technologies.
@CleClinicHVTI@ClevelandClinic
In the largest cohort of high-risk pts w/ symptomatic native AR undergoing #TAVR w/ JenaValve:
🔹The primary safety & efficacy outcomes met prespecified performance goals
-Safety - 26.2% vs 40.5%, p<0.0001
-Efficacy (all-cause mortality) - 8.1% vs. 25%, p<0.0001
#ACC25 🧵1/n